IGHE and Allergy: The Docosahexaenoic Acid to Optimise Mother Infant Outcome (DOMInO) RCT found that maternal n-3 LCPUFA supplementation (900 mg/day) during pregnancy reduced the risk of atopic eczema and egg sensitization during the first year of life but not the overall incidence of IgE-associated allergies [46].